

# Muhammad Umair Mushtaq

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1495854/publications.pdf>

Version: 2024-02-01

89  
papers

904  
citations

567144

15  
h-index

526166

27  
g-index

92  
all docs

92  
docs citations

92  
times ranked

1161  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Chronic graft-versus-host disease presenting as acute polymyositis: A case series and systematic review. <i>Transplant Immunology</i> , 2022, 70, 101520.   | 0.6 | 6         |
| 2  | Impact of COVID-19 in hematopoietic stem cell transplant recipients: A systematic review and meta-analysis. <i>Transplant Infectious Disease</i> , 2022, 24, .  | 0.7 | 28        |
| 3  | Functional characterization of NPM1-TYK2 fusion oncogene. <i>Npj Precision Oncology</i> , 2022, 6, 3.   | 2.3 | 2         |
| 4  | Gender disparities in the National Institutes of Health funding for hematologic malignancies and cellular therapies. <i>Leukemia and Lymphoma</i> , 2022, 63, 1708-1713.  | 0.6 | 6         |
| 5  | Single Institution Experience with Myeloma Patients for Commercially Approved BCMA Chimeric Antigen Receptor T Cell Therapy (CART) Idecabtagene-Vicleucel (Ide-cel). <i>Transplantation and Cellular Therapy</i> , 2022, 28, S233-S234. | 0.6 | 1         |
| 6  | Top 100 Cited Articles on Hematopoietic Stem Cell Transplantation: A Bibliometric Analysis. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S453-S454.  | 0.6 | 0         |
| 7  | Outcomes of Autologous Stem Cell Transplantation in Primary Plasma Cell Leukemia: A Systematic Review and Meta-Analysis. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S412-S413.   | 0.6 | 0         |
| 8  | Immunogenicity of Sars-Cov-2 Vaccination in Hematopoietic Stem Cell Transplant and Chimeric Antigen Receptor T-Cell Therapy Recipients. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S46-S47.                                | 0.6 | 1         |
| 9  | Outcomes with Allogeneic Hematopoietic Stem Cell Transplantation in TP53-Mutated Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S119.                           | 0.6 | 0         |
| 10 | Socioeconomic and Racial Barriers to CD19 Chimeric Antigen Receptor T Cell Therapy (CART) Access. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S208.   | 0.6 | 0         |
| 11 | Outcomes with Allogeneic Hematopoietic Stem Cell Transplantation in TP53-Mutated Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S122.                        | 0.6 | 0         |
| 12 | Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Primary Plasma Cell Leukemia: A Systematic Review and Meta-Analysis. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S416-S417.                               | 0.6 | 0         |
| 13 | Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S204.                           | 0.6 | 0         |
| 14 | Impact of CD34+ Graft Cell Dose on Outcomes after Allogeneic Peripheral Blood Stem Cell Transplantation: A Systemic Review and Meta-Analysis. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S262-S263.                        | 0.6 | 0         |
| 15 | Prospective longitudinal study of kinetics of humoral response to one, two, or three doses of SARS-CoV-2 vaccine in hematopoietic cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2022, , .                            | 1.3 | 4         |
| 16 | Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell Therapy Access. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 358-364.   | 0.6 | 40        |
| 17 | Outcomes after venetoclax with hypomethylating agents in myelodysplastic syndromes: a systematic review and meta-analysis. <i>Leukemia and Lymphoma</i> , 2022, 63, 2671-2678.  | 0.6 | 0         |
| 18 | Role of metformin in the treatment of cholangiocarcinoma: A systematic review.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16132-e16132.  | 0.8 | 0         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 158-166.  | 0.6 | 10        |
| 20 | Role of biogenetic markers in differentiation and prognosis of giant cell tumor: A systemic review.. <i>Journal of Clinical Oncology</i> , 2021, 39, e23514-e23514.   | 0.8 | 0         |
| 21 | Healthcare access disparity among U.S. cancer population and evaluation of social determinants of health using NHANES data for 2013-18.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18527-e18527.   | 0.8 | 0         |
| 22 | Outcomes with COVID-19 in patients with hematopoietic stem cell transplant and cellular therapy: A systemic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18611-e18611.   | 0.8 | 1         |
| 23 | A systematic review of post-transplant lymphoproliferative disorder after renal transplantation.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19577-e19577.  | 0.8 | 0         |
| 24 | A systematic review of post-transplant lymphoproliferative disorder after liver transplant.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19045-e19045.   | 0.8 | 0         |
| 25 | Is chimeric antigen receptor T cell (CART) a destination procedure? Lower socioeconomic class who live farther from center have less access to CART.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18562-e18562.  | 0.8 | 3         |
| 26 | Telehealth to increase access to transplant survivorship care for allogeneic stem cell transplant recipients regardless of distance to transplant center or neighborhood income.. <i>Journal of Clinical Oncology</i> , 2021, 39, e13615-e13615.                              | 0.8 | 2         |
| 27 | Various treatment options for the management of Campanacci III giant cell bone tumor.. <i>Journal of Clinical Oncology</i> , 2021, 39, e23509-e23509.   | 0.8 | 0         |
| 28 | The impact of atrial fibrillation on hospitalization outcomes for patients with chronic lymphocytic leukemia: A large database analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19508-e19508.  | 0.8 | 0         |
| 29 | Acute polymyositis presenting as chronic graft-versus-host disease: A systemic review.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19025-e19025.  | 0.8 | 0         |
| 30 | Outcomes with COVID-19 in hematopoietic stem cell transplant and cellular therapy patients.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7033-7033.   | 0.8 | 0         |
| 31 | Outcomes with venetoclax in myelodysplastic syndromes: A systematic review.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19035-e19035.   | 0.8 | 0         |
| 32 | Role of adjunct plasma exchange or high cut-off hemodialysis in the management of myeloma cast nephropathy: A systematic review.. <i>Journal of Clinical Oncology</i> , 2021, 39, e20032-e20032.  | 0.8 | 0         |
| 33 | Outcomes with preemptive donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndromes: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19014-e19014. | 0.8 | 2         |
| 34 | Outcomes with CD34 stem cell boost for poor graft function after allogeneic hematopoietic stem cell transplantation for hematologic malignancies: A systemic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19021-e19021.                        | 0.8 | 1         |
| 35 | Gender disparities in National Institute of Health funding for hematologic malignancies, hematopoietic stem cell transplantation, and cellular therapeutics.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11020-11020.  | 0.8 | 0         |
| 36 | Profile and management of toxicity of selinexor and belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma: A systematic review.. <i>Journal of Clinical Oncology</i> , 2021, 39, e20014-e20014.  | 0.8 | 0         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Management of light chain deposition disease: A systematic review.. Journal of Clinical Oncology, 2021, 39, e20042-e20042.   | 0.8 | 0         |
| 38 | A systematic review of post-transplant lymphoproliferative disorder after lung transplant.. Journal of Clinical Oncology, 2021, 39, e19046-e19046.   | 0.8 | 0         |
| 39 | Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma. ESMO Open, 2021, 6, 100172.  | 2.0 | 9         |
| 40 | Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients. Transplantation and Cellular Therapy, 2021, 27, 796.e1-796.e7.  | 0.6 | 42        |
| 41 | Outcomes with CD34-Selected Stem Cell Boost for Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. Transplantation and Cellular Therapy, 2021, 27, 877.e1-877.e8.  | 0.6 | 20        |
| 42 | Outcomes with Interferon in Essential Thrombocythemia: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 3147-3147.   | 0.6 | 0         |
| 43 | Use of Endpoints in Phase III Randomized Controlled Trials for Acute Myeloid Leukemia over the Last 15 Years: A Systematic Review. Blood, 2021, 138, 4389-4389.  | 0.6 | 0         |
| 44 | Evolution in Resource Utilization for Unique Toxicities Related to Chimeric Antigen Receptor T Cell Therapy from 2017 to 2020: A Database Review. Blood, 2021, 138, 4844-4844.   | 0.6 | 0         |
| 45 | Outcomes of Tyrosine Kinase Inhibitors Maintenance Therapy with or without Allogeneic Hematopoietic Stem Cell Transplantation in Philadelphia Positive Acute Lymphoblastic Leukemia in First Complete Remission: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 3961-3961. | 0.6 | 0         |
| 46 | Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 4825-4825.   | 0.6 | 0         |
| 47 | Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 4683-4683.  | 0.6 | 0         |
| 48 | Outcomes with Hematopoietic Stem Cell Transplantation in Secondary Hemophagocytic Lymphohistiocytosis: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 3963-3963.   | 0.6 | 0         |
| 49 | Safety and Cost Effectiveness of Chimeric Antigen Receptor T Cell Therapy in the Outpatient Setting. Blood, 2021, 138, 2823-2823.  | 0.6 | 0         |
| 50 | Outcomes with Venetoclax in Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: A Systemic Review and Meta-Analysis. Blood, 2021, 138, 4410-4410.  | 0.6 | 0         |
| 51 | Outcomes with Mismatched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 1848-1848.   | 0.6 | 0         |
| 52 | Use of Endpoints in Phase III Randomized Controlled Trials for Hematopoietic Stem Cell Transplantation over the Last 15 Years: A Systematic Review. Blood, 2021, 138, 4910-4910.   | 0.6 | 0         |
| 53 | Outcomes with Interferon in Polycythemia Vera: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 3659-3659.   | 0.6 | 0         |
| 54 | Outcomes with Natural Killer Cells Infusion after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 1847-1847.  | 0.6 | 0         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Outcomes with Mismatched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation Following Reduced Intensity Conditioning: A Systematic Review and Meta-Analysis. <i>Blood</i> , 2021, 138, 2863-2863.                  | 0.6 | 0         |
| 56 | Impact of Natural Killer Cells Reconstitution on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. <i>Blood</i> , 2021, 138, 4880-4880.                                    | 0.6 | 0         |
| 57 | Top 100 Cited Articles on Hematopoietic Stem Cell Transplantation: A Bibliometric Analysis. <i>Blood</i> , 2021, 138, 4790-4790.   | 0.6 | 0         |
| 58 | Outcomes with "Off the Shelf" Allogeneic CD19 Chimeric Antigen Receptor T Cell Therapy for Hematological Malignancies: A Systematic Review and Meta-Analysis. <i>Blood</i> , 2021, 138, 4831-4831.                                 | 0.6 | 0         |
| 59 | Comparison of Efficacy and Safety Profile of Allogeneic Versus Autologous CD19 Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies: A Systematic Review and Meta-Analysis. <i>Blood</i> , 2021, 138, 4824-4824. | 0.6 | 0         |
| 60 | Versican proteolysis predicts immune effector infiltration and post-transplant survival in myeloma. <i>Leukemia and Lymphoma</i> , 2019, 60, 2558-2562.  | 0.6 | 13        |
| 61 | Simultaneous acute myeloid leukemia, multiple myeloma, and amyloidosis. <i>Blood</i> , 2019, 134, 1270-1270.   | 0.6 | 2         |
| 62 | Versican (VCAN) Proteolysis Predicts Survival in Multiple Myeloma (MM) after High Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT/AHCT). <i>Blood</i> , 2019, 134, 3088-3088.                                  | 0.6 | 0         |
| 63 | Retrospective Analysis of Factors Associated With Venous Thromboembolism Among Pancreatic Cancer Patients. <i>Pancreas</i> , 2018, 47, e52-e53.  | 0.5 | 0         |
| 64 | Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers. , 2018, 6, 65.   |     | 118       |
| 65 | Pre-therapy neutrophil-to-lymphocyte ratio and lymphocyte-to-monocyte ratio do not predict survival in patients treated with immune checkpoint inhibitors.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15092-e15092.         | 0.8 | 1         |
| 66 | Factors Associated with Bleeding Events in Patients Receiving Rivaroxaban for Venous Thromboembolism: A Real World Experience. <i>Blood</i> , 2018, 132, 5064-5064.  | 0.6 | 0         |
| 67 | Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 5246-5246.  | 0.6 | 5         |
| 68 | Comparison of Salvage Chemotherapy Regimens in Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 2708-2708.  | 0.6 | 0         |
| 69 | Prognostic score to predict time to castration-resistance in underserved patients with metastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, e16518-e16518.   | 0.8 | 0         |
| 70 | Prognostic Significance of Bone Marrow Involvement in Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 5370-5370.   | 0.6 | 6         |
| 71 | Prognostic significance of neutrophil-to-lymphocyte ratio and lymphocyte-to-monocyte ratio in myelodysplastic syndromes.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7062-7062.   | 0.8 | 2         |
| 72 | Comparison of International Prognostic Scoring System (IPSS) and Revised IPSS (IPSS-R) in myelodysplastic syndromes (MDS).. <i>Journal of Clinical Oncology</i> , 2016, 34, e18549-e18549.   | 0.8 | 0         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | Prognostic significance of bone marrow cellularity in myelodysplastic syndromes: a retrospective analysis.. Journal of Clinical Oncology, 2016, 34, e18550-e18550.   | 0.8 | 0         |
| 74 | Aleukaemic leukaemia cutis. British Journal of Haematology, 2015, 170, 4-4.  | 1.2 | 0         |
| 75 | Association of Pre-chemotherapy neutrophil-to-lymphocyte ratio with overall survival in underserved pancreatic cancer.. Journal of Clinical Oncology, 2015, 33, e15241-e15241.   | 0.8 | 0         |
| 76 | Association of neutrophil-to-lymphocyte ratio with overall survival in underserved patients with pancreatic cancer.. Journal of Clinical Oncology, 2015, 33, e15263-e15263.  | 0.8 | 0         |
| 77 | Factors associated with venous thromboembolism among pancreatic cancerpatients.. Journal of Clinical Oncology, 2015, 33, e15285-e15285.  | 0.8 | 0         |
| 78 | Lab Indicators of Iron Level in Bone Marrow Aspirate of Patients Diagnosed with Multiple Myeloma. Blood, 2015, 126, 5397-5397.   | 0.6 | 0         |
| 79 | Height, weight and BMI percentiles and nutritional status relative to the international growth references among Pakistani school-aged children. BMC Pediatrics, 2012, 12, 31.  | 0.7 | 66        |
| 80 | Waist circumference, waist-hip ratio and waist-height ratio percentiles and central obesity among Pakistani children aged five to twelve years. BMC Pediatrics, 2011, 11, 105.   | 0.7 | 76        |
| 81 | Family-based factors associated with overweight and obesity among Pakistani primary school children. BMC Pediatrics, 2011, 11, 114.  | 0.7 | 28        |
| 82 | Prevalence and socioeconomic correlates of overweight and obesity among Pakistani primary school children. BMC Public Health, 2011, 11, 724.   | 1.2 | 47        |
| 83 | Prevalence and socio-demographic correlates of stunting and thinness among Pakistani primary school children. BMC Public Health, 2011, 11, 790.  | 1.2 | 81        |
| 84 | Urban-rural inequities in knowledge, attitudes and practices regarding tuberculosis in two districts of Pakistan's Punjab province. International Journal for Equity in Health, 2011, 10, 8.   | 1.5 | 66        |
| 85 | Dietary behaviors, physical activity and sedentary lifestyle associated with overweight and obesity, and their socio-demographic correlates, among Pakistani primary school children. International Journal of Behavioral Nutrition and Physical Activity, 2011, 8, 130. | 2.0 | 92        |
| 86 | Socio-demographic correlates of the health-seeking behaviours in two districts of Pakistan's Punjab province. JPMA the Journal of the Pakistan Medical Association, 2011, 61, 1205-9.  | 0.1 | 3         |
| 87 | Are we doing enough? Evaluation of the Polio Eradication Initiative in a district of Pakistan's Punjab province: a LQAS study. BMC Public Health, 2010, 10, 60.  | 1.2 | 27        |
| 88 | From their own perspective - constraints in the Polio Eradication Initiative: perceptions of health workers and managers in a district of Pakistan's Punjab province. BMC International Health and Human Rights, 2010, 10, 22.   | 2.5 | 19        |
| 89 | Public health in British India: A brief account of the history of medical services and disease prevention in colonial India. Indian Journal of Community Medicine, 2009, 34, 6.  | 0.2 | 47        |